188 related articles for article (PubMed ID: 15254412)
21. Chronic myelogenous leukaemia--new therapeutic principles.
O'Dwyer ME; Druker BJ
J Intern Med; 2001 Jul; 250(1):3-9. PubMed ID: 11454136
[TBL] [Abstract][Full Text] [Related]
22. Imatinib mesylate, the first molecularly targeted gene suppressor.
Pindolia VK; Zarowitz BJ
Pharmacotherapy; 2002 Oct; 22(10):1249-65. PubMed ID: 12389876
[TBL] [Abstract][Full Text] [Related]
23. Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance.
Bixby D; Talpaz M
Hematology Am Soc Hematol Educ Program; 2009; ():461-76. PubMed ID: 20008232
[TBL] [Abstract][Full Text] [Related]
24. [Targeted treatment of cancers with imatinib mesylate (STI571, Gleevec): results of Asco 2002].
Ray-Coquard I; Blay JY
Bull Cancer; 2002 Jun; 89(6):567-9. PubMed ID: 12135855
[No Abstract] [Full Text] [Related]
25. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
Cohen MH; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
[TBL] [Abstract][Full Text] [Related]
26. Spotlight on imatinib mesylate in chronic myeloid leukemia.
Curran MP; Croom KF; Goa KL
BioDrugs; 2004; 18(3):207-10. PubMed ID: 15161340
[TBL] [Abstract][Full Text] [Related]
27. Imatinib mesylate in the treatment of chronic myelogenous leukemia.
Borthakur G; Cortes JE
Int J Hematol; 2004 Jun; 79(5):411-9. PubMed ID: 15239390
[TBL] [Abstract][Full Text] [Related]
28. Imatinib (Gleevec) as a paradigm of targeted cancer therapies.
Druker B
Keio J Med; 2010; 59(1):1-3. PubMed ID: 20375651
[No Abstract] [Full Text] [Related]
29. Imatinib mesylate (Gleevec): targeted therapy against cancer with immune properties.
Zoubir M; Tursz T; Ménard C; Zitvogel L; Chaput N
Endocr Metab Immune Disord Drug Targets; 2010 Mar; 10(1):1-7. PubMed ID: 19839938
[TBL] [Abstract][Full Text] [Related]
30. Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias.
Kantarjian HM; Talpaz M
Semin Oncol; 2001 Oct; 28(5 Suppl 17):9-18. PubMed ID: 11740802
[TBL] [Abstract][Full Text] [Related]
31. Gleevec resistance: lessons for target-directed drug development.
Daley GQ
Cell Cycle; 2003; 2(3):190-1. PubMed ID: 12734421
[No Abstract] [Full Text] [Related]
32. Anti-cancer drug success emerges from molecular biology origins.
Pestell K
Trends Pharmacol Sci; 2001 Jul; 22(7):342. PubMed ID: 11431023
[No Abstract] [Full Text] [Related]
33. Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemia.
Deininger MW
J Cancer Res Clin Oncol; 2004 Feb; 130(2):59-72. PubMed ID: 14605878
[TBL] [Abstract][Full Text] [Related]
34. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
Croom KF; Perry CM
Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
[TBL] [Abstract][Full Text] [Related]
35. Changes in therapy for solid tumors: potential for overcoming drug resistance in vivo with molecular targeting agents.
Kim R; Toge T
Surg Today; 2004; 34(4):293-303. PubMed ID: 15052442
[TBL] [Abstract][Full Text] [Related]
36. Identification of differentially expressed proteins in imatinib mesylate-resistant chronic myelogenous cells.
Park J; Kim S; Oh JK; Kim JY; Yoon SS; Lee D; Kim Y
J Biochem Mol Biol; 2005 Nov; 38(6):725-38. PubMed ID: 16336789
[TBL] [Abstract][Full Text] [Related]
37. Imatinib mesylate in the treatment of hematologic malignancies.
Piccaluga PP; Rondoni M; Paolini S; Rosti G; Martinelli G; Baccarani M
Expert Opin Biol Ther; 2007 Oct; 7(10):1597-611. PubMed ID: 17916051
[TBL] [Abstract][Full Text] [Related]
38. Protein kinases as targets for anticancer agents: from inhibitors to useful drugs.
Fabbro D; Ruetz S; Buchdunger E; Cowan-Jacob SW; Fendrich G; Liebetanz J; Mestan J; O'Reilly T; Traxler P; Chaudhuri B; Fretz H; Zimmermann J; Meyer T; Caravatti G; Furet P; Manley PW
Pharmacol Ther; 2002; 93(2-3):79-98. PubMed ID: 12191602
[TBL] [Abstract][Full Text] [Related]
39. Does hope match the hype for targeted drugs?
Brown H
Lancet Oncol; 2003 Aug; 4(8):452. PubMed ID: 12918521
[No Abstract] [Full Text] [Related]
40. New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004.
Caponigro F; Basile M; de Rosa V; Normanno N
Anticancer Drugs; 2005 Feb; 16(2):211-21. PubMed ID: 15655420
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
